We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PRAC Calls for Lemtrada Restrictions, ‘Cautious Use’ of Xeljanz
PRAC Calls for Lemtrada Restrictions, ‘Cautious Use’ of Xeljanz
In an Oct. 28-31 meeting, the EMA’s pharmacovigilance risk assessment committee (PRAC) warned against the use of Sanofi’s multiple sclerosis drug Lemtrada (alemtuzumab) in patients with certain heart, circulation, bleeding or auto-immune disorders besides multiple sclerosis.